Table 1. Patient cohort.
| Total Evaluable N = 17 | |
|---|---|
| Patient Characteristics | |
| Median age (range) | 59 (45,77) |
| Gender, male (%) | 11 (65%) |
| Median residual CE tumor volume (range) | 11.97 (0.84, 59.5) |
| MGMT methylated* | 1 (6%) |
| MGMT unmethylated | 3 (18%) |
| MGMT unknown/not tested | 13 (76%) |
| Initial Treatment | |
| Temozolomide + RT | 12 (71%) |
| Temozolomide + RT+ clinical trial drug | 4 (23%) |
| Temozolomide +BSI (PARP inhibitor), but no RT | 1 (6%) |
| Salvage Therapy# | |
| None | 4 (24%) |
| RT | 1 (6%) |
| Surgery | 1 (6%) |
| Bevacizumab | 4 (24%) |
| Chemotherapy | 9 (53%) |
| NovoTTF | 9 (53%) |
| Survival | |
| Median survival time, days (95%CI) | 403 (209, 642) |
| OS-1 (%) | 10 (59%) |
| Median PFS, days (range) | 201 (128,335) |
| PFS-6 (%) | 11 (65%) |
CE contrast enhancement; RT radiation therapy
*Central review of tissue was not required and not all sites tested MGMT or patient underwent biopsy so there was insufficient tissue for MGMT testing.
# Patients could be counted more than once if received multiple salvage therapies.